HAEMONETICS CORP
For the period ended Mar 30, 2024. Filed May 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed May 20, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
As of March 30, 2024, our global headquarters are located in Boston, Massachusetts and our principal manufacturing centers are located in Pennsylvania and California within the U.S., as well as internationally in Mexico, Malaysia and Canada. Our products are distributed worldwide from primary distribution centers in Tennessee, Utah and Switzerland, as well as smaller locations globally. We believe all of these facilities are well-maintained and suitable for the operations conducted in them. These facilities produce and manufacture products for more than one of our business segments.
The following is a summary of our facilities as of March 30, 2024 (in approximate square feet):
| Owned | Leased | Total | |
|---|---|---|---|
| U.S. | 165,385 | 638,749 | 804,134 |
| International | 378,000 | 303,903 | 681,903 |
| Total | 543,385 | 942,652 | 1,486,037 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.